Family sues infant formula company after baby contracts botulism.

A troubling case of infant botulism linked to a commercial infant formula has prompted the parents of a two-month-old child to file a lawsuit against the product’s manufacturer and retailer. Erica and Micky Goldfin from Yardley, Pennsylvania, reported that their newborn son exhibited troubling symptoms including weak cries, droopy eyelids, and difficulty swallowing. These alarming signs led the family to seek emergency care at the Children’s Hospital of Philadelphia, where their infant was admitted into the intensive care unit for treatment of this rare but potentially life-threatening condition.

Infant botulism is caused by the ingestion of Clostridium botulinum toxins, which can lead to paralysis affecting the nervous system. The Goldfin family claims that the illness stemmed from Nara Organics whole milk infant formula, which they began feeding their son just days after his birth in March. Following the report of multiple cases of infant botulism associated with its formula, Nara Organics initiated a voluntary recall on June 13. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention had confirmed instances of infant botulism in Pennsylvania, California, and Washington among babies who consumed the affected formula.

In their lawsuit, filed in the U.S. District Court for the Eastern District of Pennsylvania, the Goldfins assert that Nara Organics failed to sufficiently safeguard consumers. The legal representation for the family, led by foodborne illness attorney Bill Marler, contends that parents were misled into believing the product was safe due to its marketing as a premium formula, despite federal warnings that whole milk powder can harbor botulism-causing bacteria.

The suit comes in the wake of a growing concern surrounding cases of botulism linked to powdered infant formulas, marking a second notable outbreak this year. Previously, another incident involving ByHeart formula affected at least 28 infants.

Nara Organics has stated on their website that they issued the recall out of an abundance of caution, clarifying that none of their formulas had tested positive for the botulinum toxin. The company emphasized its commitment to ensuring the safety of their products and the health of infants. Meanwhile, Target, where the formula was purchased, declined to comment on the ongoing litigation.

Botulism presents particularly high risks to infants due to their developing immune systems. In 2021 alone, there were 181 reported cases of infant botulism across the United States, according to CDC data. Affected infants may exhibit symptoms such as slow feeding, constipation, and lethargy, which can quickly escalate into more severe complications if untreated.

As for the Goldfin baby, identified only by the initials W.G., he spent two nights in the hospital where he received the botulism antitoxin known as BabyBIG, which effectively neutralizes the toxin and can lead to symptom improvement within 48 hours. Currently, he is back at home, receiving regular physical therapy to help overcome developmental delays following his hospital treatment.

This legal battle underscores the heightened scrutiny regarding the safety of infant food products, as families navigate the critical decision of providing nutritious and safe options for their children.

Media News Source.